30 closest matches · ranked by relevance
CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]
Primary: Peak Plasma Concentration (Cmax) of 2% Diltiazem — 0.340; 0.624 ng / mL
Healthy
Primary: NK-104 AUC — 208.92 ng * h/mL
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2.84; 8.44 ng/mL
Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Primary: Maximum Plasma Concentration (Cmax) — 2,172.32; 2,802.90 pg/mL
Multidrug-resistant Tuberculosis · Extensively Drug-resistant Tuberculosis
Primary: Area Under the Time Concentration Curve (AUC0-12h) of Linezolid in Plasma After Addition of 0mg, 250mg, or 500mg Clarithromycin (CLA). — 36.3; 61.0; 67.2 mg*h/L
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,968.42; 3,850.63 pg/mL
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970 — 380; 1380 nanogram*hour per milliliter…
Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5190; 5340 nmol*h/L
Jervell and Lange Nielsen Syndrome
Primary: QT Interval — 623 ms
Safety Issues · Pharmacokinetics · Drug Interaction
Primary: Period I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - AUC0-inf — 13950; 42840; 137.3; 165.9 h*nmol/L
Drug Drug Interaction
Primary: Cmax of Givinostat, Following Single Doses of the Parent Drug — 53.57; 75.35 ng/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 2440.545; 2414.955 ng/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 2170.964; 2214.636 ng/mL
Healthy
Primary: NK-104 AUC — 192.00 ng * h/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 640.08; 640.11 ng/mL
Drug-drug Interaction
Primary: AUC — 242; 642; 124; 371 ng/mL·h
Healthy
Primary: Cmax - Maximum Observed Concentration — 1515.00; 1464.10 ng/mL
Atrial Fibrillation With Rapid Ventricular Response · Hypotension Drug-Induced
Primary: Mean Difference in Systolic Blood Pressure — -11.7500; -19.5385 mmHg
Depressive Disorder, Major
Primary: Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of LY2216684 — 582; 746 nanogram*hours per milliliter (ng*h/mL)
Healthy
Primary: Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss) — 551; 817; 689; 660 ng*h/mL — p=0.9456
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 1,869.50; 4,993.06 pg/mL
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,737.00; 3,051.76 pg/mL
Helicobacter Pylori
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 53.3; 66.7 percentage of participants
Healthy Volunteers
Primary: Area Under the Curve From Time 0 to Tau (AUC 0-τ) — 113.92 ng•h/mL
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) — 94.37; 43.84; 106.35; 51.65 ng/mL
HIV Infections
Primary: Cmax of Rosuvastatin — 6.70; 16.32 ng/mL
Healthy
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] — 463.41; 498.87 ng*hr/mL
Atrial Fibrillation · Atrial Flutter
Primary: Admission Rate — 98; 188 Participants
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of LY2409021 — 34700; 35300; 38000; 145000 nanogram*hours per milliliter (ng*h/mL)
Coronary Artery Disease
Primary: TRAP-induced Platelet Aggregation — 74; 77 percentage of aggregation — p=<0.05